<DOC>
	<DOCNO>NCT01513902</DOCNO>
	<brief_summary>Phase 1 study describe pharmacokinetics CP-690,550 pediatric patient 2 less 18 year age Juvenile Idiopathic Rheumatoid Arthritis ( JIA ) .</brief_summary>
	<brief_title>Pharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis ( JIA )</brief_title>
	<detailed_description>This open-label , non-randomized , multi-center , oral CP-690,550 , multiple-dose ( twice daily 5 day [ except Day 5 morning dose give ] ) study pediatric subject JIA age 2 less 18 year . Baseline visit occur within 1 month completion Screening Visit . The study consist three cohort base age subject , Cohort 3 : 2 less 6 year , Cohort 2 : 6 less 12 year Cohort 1 : 12 less 18 year . In cohort , least 8 pediatric subject JIA participate study ensure total number least 24 pediatric evaluable subject complete PK period .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>1 . Pediatric patient JIA age 2 less 18 year active JIA ( extend oligoarthritis , polyarthritis rheumatoid factor positive negative , psoriatic arthritis , enthesitis related arthritis ) , 5 joint ( use American College Rheumatology definition active joint ) time first study drug administration . 2 . For subject receive MTX treatment , minimum duration therapy 4 month dose stable least 6 week prior first dose study drug . MTX may administer either orally parenterally dose exceed 20 mg/wk 15 mg/m2/week . 3 . A negative QuantiFERONTB Gold InTube test perform within 3 month prior screen . A negative PPD test substitute QuantiFERONTB Gold InTube test central laboratory unable perform test determine result positive negative Pfizer medical monitor approves , casebycase basis . 1 . Systemic JIA , persistent oligoarthritis , undifferentiated arthritis . 2 . Current recent history uncontrolled clinically significant renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , cardiac , neurological disease . 3 . History rheumatic autoimmune disease . 4 . Infections : 1 . Latent active TB history previous TB . 2 . Chronic infection . 3 . Any infection require hospitalization , parenteral antimicrobial therapy judge opportunistic investigator within 6 month prior first dose study drug . 4 . Any treated infection within 2 week Baseline visit . 5 . A subject know infected human immunodeficiency virus ( HIV ) , hepatitis B hepatitis C virus . 6 . History infect joint prosthesis prosthesis still situ . 5 . History recurrent ( one episode ) herpes zoster disseminate ( single episode ) herpes zoster disseminate ( single episode ) herpes simplex . 6 . The biologic agent DMARDs disallow time study . If subject need treat one agent , subject discontinue study . 7 . Subjects vaccinate live attenuate vaccine within 6 week prior first dose study medication vaccinate vaccines time treatment within 6 week follow discontinuation study drug . 8 . Subjects malignancy history malignancy exception adequately treat excised nonmetastatic basal cell squamous cell cancer skin cervical carcinoma situ .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Arthritis</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Tofacitinib</keyword>
	<keyword>JIA</keyword>
</DOC>